Heparin-induced thrombocytopenia epidemiology and demographics: Difference between revisions
(Created page with "{{Heparin-induced thrombocytopenia}} {{CMG}}; '''Associate Editor(s)-In-Chief:''' Priyamvada Singh, M.B.B.S. [mailto:psingh@perfuse.org] ==Overview== [[He...") |
No edit summary |
||
| Line 5: | Line 5: | ||
==Epidemiology and demographics== | ==Epidemiology and demographics== | ||
* [[Heparin-induced thrombocytopenia]] is diagnosed when the [[platelet]] count falls by > 50% typically after 5-10 days of [[heparin]] therapy. The affected individuals have an increased risks of having another thromboembolic event (20-50% increased risks) | |||
* Mortality rate can be as high as 20% | |||
* 1 in 10 patients suffer from other morbidities (amputations or other arterial venous or both thrombo-embolic events) | |||
===United States of America=== | ===United States of America=== | ||
* Incidences varies from 1-5%. | * Incidences varies from 1-5%. | ||
===Race=== | ===Race=== | ||
| Line 14: | Line 16: | ||
Female have increased risks compared to male for a risk of heparin-induced thrombocytopenia | Female have increased risks compared to male for a risk of heparin-induced thrombocytopenia | ||
===Age=== | ===Age=== | ||
Risks for development of HIT Increases with increased age (>60years) | Risks for development of HIT Increases with increased age (>60years) | ||
==Reference== | ==Reference== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
Revision as of 12:34, 10 December 2011
|
Heparin-induced thrombocytopenia |
|
Differentiating Heparin-induced thrombocytopenia from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Heparin-induced thrombocytopenia epidemiology and demographics On the Web |
|
American Roentgen Ray Society Images of Heparin-induced thrombocytopenia epidemiology and demographics |
|
FDA on Heparin-induced thrombocytopenia epidemiology and demographics |
|
CDC on Heparin-induced thrombocytopenia epidemiology and demographics |
|
Heparin-induced thrombocytopenia epidemiology and demographics in the news |
|
Blogs on Heparin-induced thrombocytopenia epidemiology and demographics |
|
Directions to Hospitals Treating Heparin-induced thrombocytopenia |
|
Risk calculators and risk factors for Heparin-induced thrombocytopenia epidemiology and demographics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-In-Chief: Priyamvada Singh, M.B.B.S. [2]
Overview
Heparin-induced thrombocytopenia is diagnosed when the platelet count falls by > 50% typically after 5-10 days of heparin therapy. It is caused by antibodies to complexes between heparin and platelet factor 4 (PF4). These antibody complexes stimulates the procoagulant pathways due to activation of platelet and endothelium.
Epidemiology and demographics
- Heparin-induced thrombocytopenia is diagnosed when the platelet count falls by > 50% typically after 5-10 days of heparin therapy. The affected individuals have an increased risks of having another thromboembolic event (20-50% increased risks)
- Mortality rate can be as high as 20%
- 1 in 10 patients suffer from other morbidities (amputations or other arterial venous or both thrombo-embolic events)
United States of America
- Incidences varies from 1-5%.
Race
Some studies have shown that the incidences of heparin-induced thrombocytopenia (HIT) are more common among white patients compare to non-white population.
Sex
Female have increased risks compared to male for a risk of heparin-induced thrombocytopenia
Age
Risks for development of HIT Increases with increased age (>60years)